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Abstract
Hepatitis C virus (HCV) infection affects approximately 170 million people worldwide. 
Interferon-alpha (IFN-α) is a cytokine that is related to early viral infection and has both 
antiviral and antiproliferative properties. The current standard treatment for long-term 
chronic hepatitis C (CHC) consists of combination therapy with IFN-α and ribavirin, 
which has a broad spectrum antiviral effect. Despite the potential therapeutic benefits of 
IFN-α, its administration often causes many side effects, such as somatic and neuropsy-
chiatric symptoms. Depression is a serious and frequently occurring side effect of IFN-α 
therapy, and this is one of the major reasons for cessation of the therapy. Therefore, in 
order to avoid the discontinuation of INF-α therapy owing to depressive symptoms, it 
is important to identify the risk factor(s) leading to the onset of associated depressive 
symptoms. In this chapter, we introduce our novel findings on the association between 
IFN treatment and the onset of depression in CHC patients as well as the potential neu-
robiological mechanisms by which depression may arise. We also highlight a potential 
approach for predicting the onset risk of depression as a side effect in these patients.
Keywords: hepatitis C, IFNs, depression, tryptophan catabolism, indoleamine 
2,3-dioxygenase 1
1. Introduction
Hepatitis C virus (HCV) infection is a global health problem. Up to 85% of HCV-infected 
patients may develop long-term chronic hepatitis C (CHC), a disease state associated with seri-
ous clinical sequela, including liver cirrhosis, hepatic fibrosis, and hepatocellular carcinoma 
[1–4]. It has been estimated that up to 20% of CHC patients will develop hepatic cirrhosis over 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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a 20–25-year period, and these individuals are at an increased risk for developing end-stage 
hepatic diseases or hepatocellular carcinoma [4]. Therefore, aggressive antiviral treatments to 
successfully induce viral remission constitute a major strategy for reducing the morbidity and 
mortality associated with CHC.
Immunotherapy with interferon-alpha (IFN-α) is commonly used to treat CHC and several 
types of malignancies owing to its antiviral, antiproliferative, and immunoregulatory effects [5]. 
In clinical trials, more than 50% of CHC patients treated with combination therapy using IFN-α 
and ribavirin achieved a sustained viral response, defined as undetectable HCV in the blood 
6 months following the end of treatment [4]. Despite the efficacy of IFN-α in CHC treatment, 
IFN-α therapy causes serious side effects; early signs include somatic symptoms (anorexia, 
pain, insomnia, fever, and fatigue). Prolonged therapy causes neuropsychiatric symptoms 
including depressive states, anhedonia, anxiety, and cognitive impairment. In particular, 
depression is a serious and frequently occurring side effect of IFN-α therapy, and this leads to 
discontinuation of the therapy in up to 45% of patients [6, 7]. Therefore, in order to avoid the 
discontinuation of IFN-α therapy owing to depressive symptoms induced by the cytokine, it is 
important to identify the risk factor(s) leading to the associated depressive symptoms.
A number of findings suggest that the neuropsychiatric side effects observed during IFN-α 
therapy may be linked to aberrations in the tryptophan (TRP)-kynurenine (KYN) pathway 
[8, 9]. Clinical studies have found that IFN-α therapy reduces plasma TRP and serotonin 
(5-hydroxythrptamine; 5-HT) levels [8] and increases KYN levels in plasma and cerebrospi-
nal fluid (CSF). In addition, the KYN/TRP ratio, an index of indoleamine 2,3-dioxygenase 1 
(IDO1) activity, is increased in patients receiving IFN-α therapy [8].
IDO1 is an extrahepatic enzyme that catalyzes the conversion of TRP to KYN, which can 
produce many neuroactive metabolites such as 3-hydroxykynurenine (3-HK), kynurenic acid 
(KA), and quinolinic acid (QUIN). Intriguingly, QUIN levels in CSF have been found to cor-
relate with the severity of depressive pathology [10], and post-mortem studies have shown 
increased microglia QUIN levels in the frontal cortex of severely depressed patients [11].
In the current chapter, we present the findings of our latest study, which demonstrates the 
association between IFN treatment and changes in the TRP-KYN pathway in the blood of 
HCV patients. To do so, we investigated the effect of chronic Ifn gene expression on depres-
sion-like behavior and levels of brain TRP-KYN metabolites in mice. Our results suggest the 
possibility for the prediction of onset risk of depression as a side effect in HCV patients.
2. Molecular characteristics and antiviral mechanisms of interferons 
(IFNs)
2.1. Classification of IFNs
IFNs were first introduced in 1957 as antiviral molecules. Based on their receptor types on the 
cell membrane surface, IFNs are classified into type I and type II. IFN type I mainly consists of 
IFN-α/β, while IFN type II consists of IFN-γ. IFN type I is a family of cytokines in which their 
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amino acid sequence similarity reaches 30–80%. They are produced by a wide variety of cells, 
including fibroblasts, epithelial cells, and hepatocytes [12, 13]. However, in most viral infec-
tions, plasmacytoid dendritic cells (pDCs) are probably the major source of these cytokines. 
In contrast, IFN type II (IFN-γ) is a single gene cytokine unrelated in structure to IFN-α/β, 
which is produced largely by macrophages, natural killer (NK) cells, and T lymphocytes [12].
2.2. Immune response for HCV infection and IFN induction
The host response against HCV infection is first triggered when a pathogen-associated molec-
ular pattern (PAMP), presented by an infecting virus, is recognized and engaged by specific 
PAMP receptors expressed on the host cells. This leads to the activation of signals that ulti-
mately induce the expression of antiviral effector genes [14, 15] (Figure 1). For RNA viruses, 
protein, and nucleic acid products of infection or replication have been identified as viral 
PAMPs. These are engaged by specific toll-like receptors (TLRs) or nucleic acid-binding pro-
teins that serve as PAMP receptors [15–17]. The viral RNA of HCV contains each of these 
PAMP signatures, and is adequate to trigger the host response when introduced into naïve 
cells [18, 19]. In hepatocytes, which is the target cell of HCV infection, independent pathways 
Figure 1. The host innate response to HCV infection. Adapted from Ref. [14]. (1) HCV RNA binding to RIG-I or TLR3 
results in the activation IRF-3. The dimer of phospho-IRF-3 translocates to the nucleus, interacts with transcription 
partners and binds to the cognate-DNA PRD in the promoter region of IRF-3 target genes. (2) IRF-3 activation leads to 
the induction of IFN-β production. (3) Secreted IFN-β from the infected cells binds to the IFN-α/β receptor, and results in 
activation of the JAK-STAT pathway. The ISGF3 complex translocates to the nucleus, where it binds to the ISRE on target 
genes to direct ISG expression. IRF-7 is one of the ISGs and it is activated after expression through viral PAMP signaling. 
(4) The IRF-7 dimer and heterodimer with IRF-3 binds to VRE in the promotor region of IFN-α genes resulting in the 
production of various IFN-α subtypes and establishing a positive-feedback loop for IFN amplification. It is the IFN-α 
component of the host response that is exploited by the current IFN-based therapy for HCV infection [14].
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of retinoic acid-inducible gene I (RIG-I) and TLR3 signaling construct two major pathways of 
host defense triggered by double-stranded (ds) RNA [19–21]. Viral PAMP binding to RIG-I or 
TLR3 results in the phosphorylation and activation of interferon regulatory factor 3 (IRF-3) by 
TANK-binding kinase 1 (TBK-1) and I kappa B kinase ε (IKK-ε) [14, 22]. The dimer of phos-
pho-IRF-3 translocates to the cell nucleus, interacts with its transcription partners, including 
CREB-binding protein (CBP)/p300, and binds to the cognate-DNA positive regulatory domain 
(PRD) in the promoter region of IRF-3 target genes, such as IFN-β [14, 23]. The engagement 
of PAMP receptors also leads to the synthesis of IFN-α/β, tumor necrosis factor (TNF), and a 
variety of other cytokines, which are largely produced by mainly pDCs that express TLRs in 
abundance. IFN-α/β produced by pDCs activates NK cells, thereby enhancing their cytotoxic 
potential and stimulating their production of IFN-γ. IFN-α/β produced by pDCs also modu-
lates the activation of CD8+ T cells, which produce additional IFN-γ and represent the central 
players in the pathogen-specific adaptive immune response [12].
2.3. The antiviral effect of IFNs on HCV
IFN-α mediates a wide range of biological activities including antiproliferation, immuno-
modulation, and antiviral responses. IFN-α/β acts to induce the antiviral response in cells. 
These cells can be far from IFN-α/β production site and IFN-α/β interacts with specific cell 
surface receptors, type I IFN receptors (interferon-alpha receptor 1 (IFNΑR1) and IFNΑR2; 
Figure 1). IFNARs signal to the nucleus via Janus kinase-1 (Jak1) and tyrosine kinase 2 (Tyk2) 
phosphorylation of the signal transducers and activators of transcription (STATs) [24]. The 
classic IFN-α/β signaling pathways activate STAT1/STAT2 heterodimers and the trimeric 
IFN-stimulated gene factor (ISGF) complex containing IRF-9, which activate the expression of 
specific subsets of genes controlled by promoters containing interferon-stimulated response 
elements (ISRE; Figure 1) [15]. Interferon-stimulated genes (ISGs) are the genetic effectors 
of the host response, although the details of the signaling mechanisms by which IFN-α/β 
and IFN-γ induce the transcription of ISGs are still being defined [25]. IRF-7 is a transcrip-
tion factor and an ISG. It is expressed in many tissue types, including complex liver tissue, 
in response to IFN. IRF-7 is activated after expression via viral PAMP signaling pathways 
that overlie with the IRF-3 activation pathway. IRF-7 phosphorylation, dimerization, and het-
erodimerization with IRF-3 lead to bind its cognate virus-responsive element (VRE) in the 
promotor region of IFN-α genes. Then, this binding results in the production of various IFN-α 
subtypes. The transcription effector action of IRF-7 also promotes diversification of the ISG 
response, establishing a positive-feedback loop that amplifies IFN production, and antivi-
ral action [14]. This increases the plenty of RIG-I and viral PAMP signaling modules whose 
continued signaling acts to amplify IFN production and the host response. The medicinal 
administration of IFN-α promotes an antiviral reaction against HCV infection by stimulating 
ISG expression via the IFN-α/β receptor and the JAK-STAT pathway. In addition to stimulat-
ing ISG expression, IFN-α induces or promotes the maturation of immune effector cells, and 
enhances the production of other cytokines by resident hepatic cells to indirectly modulate 
the cell-mediated defenses and adaptive immunity to HCV [15]. Viral trigger and control of 
the host response may elucidate cellular tolerance for HCV RNA replication and influence the 
outcome of infection.
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Figure 2. Schematic overview of the TRP-KYN pathway. IDO1 catabolizes L-TRP to N-formyl-L-kynurenine, which 
is converted to L-KYN by formamidase. L-KYN is further metabolized to AA by kynureninase (KYNU), to KA by 
kynurenine aminotransferases (KATs), and to 3-HK by kynurenine 3-monooxygenase (KMO). KMO is then metabolized 
to 3-HAA by 3-hydroxyanhranilate 3,4-dioxygenase (3-HAAO). 3-HAA is further metabolized to QUIN.
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3. Side effect: IFN-induced depression and tryptophan metabolism
IFN-α has been shown to develop depression in many diseases, not only CHC, but also in 
melanoma, chronic myelogenous leukemia, and renal cell carcinoma [26]. However, CHC 
patients may be more susceptible to developing IFN-induced depression than patients with 
other disorders, possibly due to a baseline 5-HT system dysfunction. Depression in CHC 
patients may result from changes in platelet 5-HT function, with decreased 5-HT concentra-
tions during CHC infection compensated for by a decrease in reuptake and metabolism [1]. 
Immune activation, particularly by IFN-γ, affects the catabolism of TRP, a precursor of 5-HT, 
by inducing expression of IDO1. IDO1 is the first and rate-limiting enzyme that converts TRP 
to N-formyl-L-kynurenine, which is further metabolized to QUIN (Figure 2). IFN treatment of 
CHC patients results in a decrease in plasma TRP and an increase in plasma KYN [8]. Another 
clinical study with cancer patients has shown that immunotherapy with IFN-α significantly 
increases the severity of depressive symptoms, which is related to a depletion of serum 5-HT 
and induction of the catabolism of TRP to KYN [27]. Thus, TRP catabolism switches from the 
5-HT pathway to the KYN pathway, resulting in a decrease in 5-HT levels.
IDO1 is induced by several pro-inflammatory cytokines including IFNs (IFN-α/β, γ), TNF-α, 
and interleukin 6 (IL-6). It is also widely accepted that IFNs, especially IFN-γ, are essential fac-
tors for IDO1 induction since two ISREs and IFN-γ-activated site (GAS) element sequences are 
found in the 5′-flanking region of the IDO1 gene [28]. Recent preclinical studies in mice have 
demonstrated that pharmacological inhibition of IDO1 enzymatic activity or genetic deletion 
of IDO1 abrogates acute and chronic inflammation-dependent behavioral changes induced by 
peripheral or central administration of lipopolysaccharide (LPS) [29–33]. Additionally, it has 
been reported that peripheral administration of KYN alone can induce depression-like behav-
ior in rats [34]. In a clinical study, patients receiving IFN-α therapy showed increases in the total 
Montgomery-Asberg Depression Rating Score (MADRS), an index of depressive symptoms 
similar to the KYN/TRP ratio; this indicates IDO1 activity and the KYN/KA ratio, which reflects 
a neurotoxic challenge [35]. These findings suggest that only TRP depletion itself may not be 
required for the induction of behavioral changes as a result of IDO1 activation; and that KYN 
and its neuroactive metabolites are more related to cytokine-induced depression-like behaviors 
than TRP depletion. However, it is still unclear whether direct activation of IDO1 and KYN 
metabolites plays a definitive role in the induction of depressive symptoms by IFN-α treatment.
4. The association between IFN treatment and changes in the TRP-KYN 
pathway on depression as a side effect in humans and mice
4.1. Changes in the levels of serum TRP and its metabolites in HCV patients with IFN-α 
therapy
In order to further clarify the relationship between the IDO1-induced KYN pathway and the 
development of depressive symptoms during IFN-α therapy, we conducted a study in which 
we measured TRP metabolites of the KYN pathway in the serum of HCV patients undergoing 
IFN-α therapy.
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A total of 49 patients (32 males and 17 females; mean age 54.0 ± 2.3 years) suffering from 
CHC were recruited. Table 1 shows the clinical characteristics of patients with HCV. In 
this study, most of patients were treated with recombinant (r) IFN-α 2b or pegylated 
(PEG)-IFN-α 2b (21 patients (42.9%) received each medicine, respectively). Five patients 
(10.2%) were treated with natural (n) IFN-α, and others received PEG-IFN-α 2a (2.0%) 
and rIFN-α 2a (2.0%), individually. All interferons have almost the same efficiency and 
induce about the same activation of the KYN pathway [36]. No patient had a past record 
of psychiatric treatment, and all were off from depressive symptoms prior to IFN-α treat-
ment. They did not take any antidepressant medications during the study period. At an 
average of 104.2 ± 15.8 days after the IFN-α administration, some patients presented with 
apathy, social isolation tendencies, melancholy, depressed mood, and an intention to 
stop IFN administration. Patients who felt depressed mood were referred for psychiatric 
(a) Clinical characteristics of HCV patients
Depression (−) Depression (+)
All subjects 30 (male: 20; female:10) 19 (male: 12; female: 7)
Age 54.33 ± 2.06 54.0 ± 2.29
HCV genotype 1b 24 (80%) 15 (78.9%)
HCV genotype 2a 4 (13.3%) 3 (15.8%)
HCV genotype 2b 2 (6.7%) 1 (5.3%)
AST 59.43 ± 5.09 57.47 ± 6.45
ALT 82.68 ± 11.36 69.56 ± 8.65
“Depression (−)”: HCV patients without depression, “Depression (+)”: HCV patients with depression following IFN-α 
therapy [47]. HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
(b) The time points of blood sampling
Time points Depression (−) (mean ± SEM) Depression (+) 
(mean ± SEM)
t df p value
(a) Before the onset of therapy 1–35 d (6.3 ± 1.8 d) 0–22 d (6.7 ± 
1.3 d)
0.230 48 0.819
(b) 2 w after the onset of therapy 13–15 d (13.8 ± 0.1 d) 12–15 d (13.6 ± 
0.2 d)
0.513 61 0.610
(c) 4 w after the onset of therapy 25–30 d (27.9 ± 0.1 d) 25–29 d (27.6 ± 
0.3 d)
0.952 40 0.347
(d) The period of therapy 167–343 d (252.0 ± 15.7 d) 54–337 d (183.4 
± 22.0 d*)
2.592 46 0.013
For all HCV patients, blood was collected before the onset of IFN-α therapy, as well as 2 and 4 weeks after the onset of 
therapy, and after the end or cessation of therapy. See Figure 3a for a detailed blood sampling schedule.*p<0.05 versus 
Depression (−) [47].
Table 1. Clinical information for HCV patients undergoing IFN-α therapy.
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evaluation and identified as major depressive disorder (MDD) by a psychiatrist. Nineteen 
of the HCV patients were diagnosed with depressive symptoms [depression (+)], while 
30 of them did not present depressive symptoms [depression (−)]. The diagnosis to verify 
the incidence of depressive symptoms associated to MDD was made according to the 
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders fourth edition) and ICD-
10 (International Statistical Classification of Disease and Related Health problems-10) 
base on clinical interviews.
For all HCV patients, blood was collected before the onset of IFN-α therapy as well as 2 and 4 
weeks after initiation of treatment. There was a no significant time difference for blood sam-
pling between depression (−) and (+) patients (Table 1b and Figure 3).
Previous studies suggested that IDO1-mediated TRP metabolism could be implicated in 
the development of depression, as a side effect of IFN-α therapy in HCV patients. We also 
found that HCV patients showed decreased TRP and increased KYN concentrations with-
out any changes in KA, AA, and 3-HAA concentrations during IFN-α therapy (Figure 3b 
and Table 2a). Furthermore, depression (+) patients presented a higher increase in 3-HK 
concentration compared to depression (−) patients during treatment (Table 2a). Ogawa 
et al. recently showed that plasma TRP concentration was significantly decreased in MDD 
patients compared to healthy controls [37]. Teraishi et al. also demonstrated increased KYN 
metabolites along the TRP-KYN-QUIN pathway, but not the KYN-KA pathway, in MDD 
patients [38]. Our results showed that the level of 3-HK in the serum significantly increased 
in depression (+) patients are consistent with these findings. We also investigated the ratios 
of 3-HK/KA (reflecting neurotoxic indices) [39, 40] and KYN/TRP (reflecting IDO1 activity) 
in depression (−) and depression (+) HCV patients during IFN-α treatment (Figure 3c and 
Table 2b). The ratios of KYN/TRP and 3-HK/KA in both groups increased during treat-
ment. However, in depression (+) patients, the ratios of KYN/TRP and 3-HK/KA increased 
much larger in depression (−) patients during treatment (Table 2b). In these patients, the 
serum KYN/TRP and 3-HK/KA ratios increased more at the diagnosis of depression, but at 
70.3 ± 9.1 days post therapy, they returned to the same levels as before onset of the therapy 
(data not shown). The severity of depression was not assessed during treatment, using 
neither the MADRS nor Hamilton Depressing Rating Scale. Therefore, we could not clearly 
show the direct association between the aggravation of depressive symptoms and changes 
in TRP metabolites. However, our results suggest that HCV patients with a high sensitivity 
for IDO1 activation by IFNs are highly susceptible to the depression-related side effects of 
IFN-α treatment.
4.2. The effects of chronic Ifn-γ gene expression on depression-like behavior in mice
We hypothesized that the high induction of IDO1 and the imbalance of TRP metabolites 
induced by IFNs in humans may be related to psychiatric side effects, such as depression. 
Previous studies have shown that all three IFNs (IFN-α, -β, and -γ) induce strong IDO1 activity 
in human peripheral blood mononuclear cells [41, 42]. In contrast, in mouse, IDO1 is induced 
more markedly by IFN-γ than IFN-α, which has only a weak direct IDO1-stimulatory effect. 
Therefore, we investigated whether IDO1 activity induced by Ifn-γ gene transfer impaired 
behavior in mice.
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Figure 3. Changes in the levels of serum TRP and its metabolites in HCV patients receiving IFN-α therapy. Original data 
from Ref. [47]. (a) Schematic depiction of the collection schedule for blood sampling from depression (−) and depression 
(+) HCV patients. The range of time points and average collection time point (a−d) per group are listed in Table 1b. (b) 
Serum TRP, KYN, KA, and 3-HK concentrations in HCV patients at 2 and 4 weeks after the onset of therapy, expressed as a 
percentage of the concentration before IFN-α therapy. (c) Serum KYN/TRP and 3-HK/KA ratios in HCV patients are shown 
as a percentage of values before IFN-α therapy. Rectangles indicate non-depressive HCV patients [Depression (−)] and circles 
indicate HCV patients with depressive symptoms [Depression (+)]. Each data point represents the mean ± SEM of values 
obtained from n = 30 depression (−) patients and n = 19 depression (+) patients. *p<0.05, ***p<0.001 versus before the onset of 
IFN-α therapy, #p<0.05, ##p<0.01 versus depression (−) patients. Detailed statistical analyses are shown in Table 2 [47].
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(a) Changes in the levels of serum TRP and its metabolites
% of value before IFN-α therapy t df p value
Depression (−) Depression (+)
2 w after onset of therapy
TRP 95.4 ± 2.93 100.5 ± 3.98 0.965 40 0.340
KYN 108.6 ± 4.77 118.1 ± 4.24* 1.200 39 0.237
3-HK 117.0 ± 7.13 152.6 ± 10.4***, ## 2.886 38 0.006
KA 97.4 ± 5.51 95.9 ± 7.13 0.136 38 0.892
AA 119.9 ± 7.42 115.5 ± 7.11 0.381 41 0.706
3-HAA 102.9 ± 6.53 121.8 ± 12.6 1.452 37 0.155
4 w after onset of therapy
TRP 92.0 ± 2.55 93.3 ± 6.49 0.213 39 0.833
KYN 104.8 ± 4.38 114.4 ± 6.38 1.204 39 0.236
3-HK 123.0 ± 9.01 155.0 ± 11.5*** 2.005 36 0.053
KA 91.9 ± 5.12 88.8 ± 6.98 0.341 40 0.735
AA 107.5 ± 5.32 103.6 ± 11.3 0.361 40 0.720
3-HAA 101.9 ± 6.52 104.5 ± 14.8 0.182 36 0.857
Percent value of serum TRP, KYN, 3-HK, KA, AA, and 3-HAA concentrations in HCV patients at 2 and 4 weeks after the 
onset of therapy, compared to the concentration (100%) before IFN-α therapy. In the clinical samples, some metabolites 
were difficult to separate clearly by HPLC. Therefore, the degree of freedom (df) values differ by the measured molecules. 
“Depression (−)”: HCV patients without depression, “Depression (+)”: HCV patients with depression.*p<0.05,
***p<0.001 versus before the therapy;
##p<0.01 versus Depression (−) [47].
(b) Changes in serum KYN/TRP and 3-HK/KA ratios
% of value before IFN-α therapy t df p value
Depression (−) Depression (+)
2 w after onset of therapy
KYN/TRP 115.6 ± 4.55 114.1 ± 5.95 0.198 42 0.844
3-HK/KA 129.1 ± 9.52 144.0±9.06* 1.036 39 0.308
4 w after onset of therapy
KYN/TRP 115.7 ± 5.69 138.3±8.84*,# 2.094 35 0.044
3-HK/KA 129.6 ± 8.67 171.1 ± 18.6***,# 2.325 35 0.026
Serum KYN/TRP reflects IDO1 activity, and 3-HK/KA reflects neurotoxic indices. Both ratios in HCV patients were shown 
as % of value compared to the value (100%) before IFN-α therapy, at 2 and 4 weeks after the onset of therapy.*p<0.05,
***p<0.001 versus before the therapy;
#p<0.01 versus Depression (−) [47].
Table 2. Changes in TRP-KYN pathway in HCV patients undergoing IFN-α therapy.
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To conduct this experiment, for murine Ifn-γ gene transfer, the plasmid pCpG-Muγ was 
constructed by inserting a BglII/NheI murine Ifn-γ cDNA fragment into the BglII/NheI site 
of the pCpG-mcs vector (Figure 4a). The prepared plasmid pCpG-Muγ was dissolved in 
normal saline and injected into the tail veins of the mice for over 5 s on day 0. The injection 
volume was approximately 9% (v/w) of body weight. To eliminate the possibility of tissue 
damage or inflammation by the hydrodynamic injection, a control plasmid, which was the 
empty vector without the Ifn-γ gene (pCpG-mcs), was injected (0.05 pmol/mouse; IFN-γ 
transfected (−) mice). A previous study demonstrated that sustained IFN-γ concentrations 
were observed in mice receiving pCpG-Muγ at a dose of 0.2 pmol/mouse and more than 
1000 pg/mL of IFN-γ was detected in the serum from 6 to 31 days after injection of pCpG-
Muγ [43]. We also confirmed that the injected plasmid, pCpG-Muγ (IFN-γ transfected 
(+) mice) significantly increased IDO1 activity in the frontal cortex over a dose of 0.05 
pmol/mouse compared to IFN-γ transfected (−) mice (Figure 4c). Therefore, the plasmid 
dose was fixed at 0.05 pmol/mouse for subsequent experiments, which corresponded to 
0.10–0.12 μg of DNA/mouse.
Figure 4. Ifn-γ gene transfer. Original data from Ref. [47]. (a) Schematic depiction of the pCpG-Muγ plasmid construct 
(InvivoGen, San Diego, CA). (b) Schematic depiction of the time schedule for animal experiments. (c) Increase of IDO1 
activity in the frontal cortex of mice 28 days after Ifn-γ gene transfer [47]. βGlo MAR, β-globin matrix attachment region; 
mCMV enh, mouse cytomegalovirus enhancer; hEF1 prom, human elongation factor1 promoter; I140, synthetic 5′UTR 
containing an intron 140; MCS, multi cloning site; SV40 pAn, Simianvirus 40 polyadenylation; IFN-β S/MAR, interferon 
β gene scaffold/matrix attachment region; EM2K, CpG-free version of the bacterial EM7 promoter; Zeo, Zeocin; R6K ori, 
R6K origin.
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In order to clarify whether the activation of IDO1 by IFN-γ-affected behaviors, three tests, 
open-field test (OFT), the Y-maze test, and forced swimming test (FST), were performed in 
mice. Mice were transfected with either a pCpG-mcs plasmid (control vector) that did not 
contain the Ifn-γ gene [IFN-γ-transfected (−) mice] or a pCpG-Muγ plasmid that long-lasting 
expressed Ifn-γ [IFN-γ transfected (+) mice]. No significant differences in locomotor activ-
ity of the OFT was observed between IFN-γ transfected (−) and (+) mice. Similarly, in the 
Y-maze test, no significant differences in the alternation behavior were detected between the 
two groups of mice. However, in the FST, immobility time was significantly longer in IFN-γ-
transfected (+) mice (Figure 5a). Our findings strongly suggest that IDO1 induction by IFN-γ 
is a critical factor in depression-like behaviors but not in short-term memory or locomotor 
activity in mice.
4.3. Changes in the levels of TRP and its metabolites in the serum and frontal cortex of 
mice following chronic Ifn-γ gene expression
In order to further elucidate the relationship between the IDO1-induced KYN pathway and 
the development of depression-like behavior in mice transfected with the pCpG-Muγ plas-
mid, we measured TRP metabolites in the serum and frontal cortex of these mice.
The serum and the frontal cortex were corrected from mice immediately following behavioral 
testing to determine the levels of TRP, KYN, KA, 3-HK, 3-HAA, and AA (Figure 5b and c). The 
concentration of serum TRP was significantly decreased in IFN-γ transfected (+) mice com-
pared to IFN-γ-transfected (−) mice. In contrast, the levels of serum KYN and 3-HK were sig-
nificantly increased in the IFN-γ-transfected (+) mice (Figure 5b). In the frontal cortex, IFN-γ 
transfected (+) mice had significantly higher KYN and 3-HK levels than the IFN-γ-transfected 
(−) mice. The TRP and KA levels in the frontal cortex tended to be lower in the IFN-γ-transfected 
(+) mice (Figure 5c). The activation of IDO1 by Ifn-γ gene transfer significantly modified the 
levels of TRP and its metabolites not only in the serum, but also in the frontal cortex of mice. 
These results suggest that an alternative explanation for the participation of IDO1 in IFN-
γ-induced depression-like behavior is the generation of neuroactive TRP metabolites. This 
interpretation is consistent with our clinical data and previous studies by O’Connor et al. 
and Wichers et al. [32, 35].
4.4. The effects of Ido1 gene-deficiency on depression-like behavior, changes in TRP 
metabolism, 5-HT, and its turnover in the frontal cortex of mice following chronic Ifn-γ 
gene expression
Additionally, we evaluated the role of IDO1 in the development of depression-like behavior 
after Ifn-γ gene transfer using Ido1 gene knockout (KO) mice, and determined the levels of 
TRP metabolites in the frontal cortex.
The increase in time spent in an immobile posture in the Ifn-γ-transfected (+)/wild type mice 
was significantly improved in Ido1 KO mice (Figure 6a). In wild type mice, Ifn-γ gene transfer 
significantly increased the concentrations of KYN and 3-HK in the frontal cortex by 4.7- and 
2.5-fold, respectively. In contrast, Ido1 KO mice withdrew these changes in Ifn-γ gene transfer 
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Figure 5. The effect of chronic Ifn-γ gene expression on the TRP-KYN pathway and depression-like behavior in mice. 
Original data from Ref. [47]. (a) Behavioral changes in mice 28 days after Ifn-γ gene transfer. Open field test shows 
locomotor activity of mice in a novel environment. Y-maze test shows short-term memory. Forced swim test shows 
depression-like behavior. Immobility time was significantly increased in IFN-γ-transfected (+) mice, compared to IFN-
γ-transfected (−) mice. The open bar shows IFN-γ-transfected (−) mice, and the closed bar shows IFN-γ-transfected (+) 
mice. Each column represents the mean ± SEM (n = 9–16). *p <0.05 versus IFN-γ-transfected (−) mice. (b) (c) Changes in the 
levels of TRP and its metabolites in the serum and frontal cortex of mice after Ifn-γ gene transfer. TRP-KYN metabolite 
concentrations were determined in the serum (b) and the frontal cortex (c) of mice 35 days after Ifn-γ-gene transfer. 
The open bar shows IFN-γ-transfected (−) mice, and the closed bar shows IFN-γ-transfected (+) mice. Each column 
represents the mean ± SEM (n = 15–20). **p<0.01, ***p<0.001 versus IFN-γ-transfected (−) mice [47].
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Figure 6. The effects of Ido1 gene-deficiency on depression-like behavior, changes in TRP metabolism, 5-HT, and its turnover 
in the frontal cortex of mice following chronic Ifn-γ gene expression. Original data from Ref. [47]. (a) Abnormal behavior 
in a forced swimming test after Ifn-γ gene transfer in mice was improved in Ido1 gene deficient mice. The Y axis shows the 
percent value of immobility time in IFN-γ-transfected (+) mice, compared to the time (100%) in IFN-γ-transfected (−) mice 
(n = 8–15). (b) The level of TRP metabolites in the frontal cortex of mice 35 days after Ifn-γ-gene transfer (n = 6–15). (c) The 
amount of 5-HT, 5-HIAA, and 5-HIAA/5-HT ratio as an index of serotonin turnover in the frontal cortex of mice 35 days 
after Ifn-γ-gene transfer (n = 6–15). The open bar represents wild type and the closed bar, Ido1 gene deficient mice. IFN-
γ-transfected (−) mice were injected with the control plasmid (pCpG-mcs), and IFN-γ-transfected (+) mice were injected 
with the IFN-γ-expressing pCpG-Muγ plasmid. Each column represents the mean ± SEM. *p<0.05, ***p<0.001 versus IFN-γ-
transfected (−) wild type mice, #p<0.05, ##p<0.01, ###p<0.001 versus IFN-γ-transfected (+) wild type mice [47].
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mice (Figure 6b). The levels of KYN and 3-HK in the frontal cortex after Ifn-γ gene transfer were 
considerably lower in Ido1 KO mice than in wild type mice. Even though we cannot exclude 
the possibility that genetic deficient in Ido1 and the resulting modifications in TRP metabolites 
could influence other behavioral tests, our results clearly demonstrate that Ido1 KO mice do not 
show depression-like behavior and do not intensify TRP metabolites after Ifn-γ gene transfer.
Other studies have emphasized that the 5-HT pathway is also relevant to depression. In a clini-
cal study, it has been shown that levels of TRP and 5-hydroxytryptophan, a precursor of 5-HT, 
were significantly decreased from their baseline levels in the serum of HCV patients dur-
ing IFN-α therapy [44]. Thus, we speculate that biological mechanisms underlying the IFN-α 
treatment induced-depressive symptoms are linked not only to the activated IDO1 and KYN 
pathway but also to a dysfunction of the 5-HT system. To clarify on the basis of the neurotrans-
mitter changes in depression-like behavior after Ifn-γ gene transfer, we measured the concen-
trations of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the frontal cortex 
of wild type and Ido1 KO mice (Figure 6c). We showed that Ifn-γ gene transfer produced a 
trend toward increased 5-HIAA levels in wild type mice but not in Ido1 KO mice. These results 
indicated that Ifn-γ gene transfer induced a potential increase in IDO1-induced 5-HT turnover. 
A raised 5-HT turnover suggests a process by which the availability of 5-HT to be released by 
neurons is decreased to compensate for neuronal dysfunction associated with depression-like 
behavior promoted by Ifn-γ gene transfer. Correspondingly, previous clinical studies have 
shown that brain 5-HT turnover is significantly increased in MDD patients without medica-
tion and decreased following selective serotonin reuptake inhibitors (SSRI) therapy [45, 46].
Taken together, an alternative interpretation for the involvement of IDO1 in IFN-γ-induced 
depression-like behavior may be that depression is related to not only the generation of neu-
roactive TRP metabolites but also to the alteration of serotoninergic neurotransmission.
5. Conclusion
The levels of TRP metabolites in the serum of HCV patients changed significantly. In par-
ticular, the increase in serum 3-HK concentration in depressive HCV patients was much 
larger than that in HCV patients without depressive symptoms. The ratios of serum KYN/
TRP, reflecting IDO1 activity, and 3-HK/KA were increased in depressive and non-depressed 
HCV patients with therapy. However, the increase in serum KYN/TRP and 3-HK/KA ratios 
in depressive patients was much higher than that of non-depressive HCV patients. When the 
Ifn-γ gene was transfected into normal mice, depression-like behavior significantly increased. 
Additionally, Ifn-γ gene transfer to mice induced dramatic changes in TRP metabolite con-
centrations in the serum and the prefrontal cortex. On the other hand, genetic deletion of 
Ido1 abrogated the enhanced depression-like behavior after Ifn-γ gene transfer. In conclusion, 
our results clearly show that IDO1 is a critical molecular regulator of the depressive pathol-
ogy induced as a side effect of interferon therapy. Moreover, the depressive symptoms are 
induced via increases in degradation of TRP and neuroactive metabolites along the KYN 
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pathway, which finally changes in the alternation of 5-HT turnover. Our findings suggest 
that inflammatory pathways that lead to the activation of IDO1 may be a novel therapeu-
tic target in patients suffering from inflammation-associated depression, for example, HCV 
or cancer therapy. Our results also suggest the monitoring of TRP-KYN metabolites during 
immunotherapy might assist in predicting the onset risk of depression as a side effect in these 
patients. However, further insight into the role of each downstream KYN pathway metabo-
lite in the pathological process is needed to understand, and to clarify the relationship with 
complex neurotransmitters.
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